Treatment of organ transplant-related lymphoma.
First described in organ transplant recipients in 1968, post-transplant lymphoproliferative disorder (PTLD) remains an often devastating complication of immunosuppression. Similar, if not identical, Epstein-Barr virus (EBV)-associated B lymphoproliferations have since been described in congenital and other acquired immunodeficiency states. Although PTLD is often morphologically indistinguishable from aggressive non-Hodgkin's lymphoma, the pathogenesis, presentation, clinical course, and management options differ significantly from those of classic NHL.
Swinnen
L J
LJ
Department of Medicine, Loyola University, Chicago, Maywood, Illinois, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000453:epidemiology; D004854:Herpesvirus 4, Human / Q000254:growth & development / Q000472:pathogenicity; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy* / Q000821:virology; D011183:Postoperative Complications / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000628:therapy* / Q000821:virology; D011994:Recombinant Proteins; D014180:Transplantation / Q000009:adverse effects*; D014412:Tumor Virus Infections / Q000453:epidemiology; D014775:Virus Activation
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins